BRYAN BURT to Pleural Neoplasms
This is a "connection" page, showing publications BRYAN BURT has written about Pleural Neoplasms.
Connection Strength
8.937
-
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.
Score: 0.722
-
Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy. J Thorac Cardiovasc Surg. 2023 01; 165(1):364-368.
Score: 0.672
-
Diagnostic Laparoscopy Improves Staging of Malignant Pleural Mesothelioma With Routine Positron Emission Tomography Imaging. Ann Thorac Surg. 2021 11; 112(5):1568-1574.
Score: 0.621
-
Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma. Ann Thorac Surg. 2021 11; 112(5):1575-1583.
Score: 0.620
-
Preoperative prediction of unresectability in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2020 06; 159(6):2512-2520.e1.
Score: 0.579
-
To slay a dragon: Timing of chemotherapy in resectable pleural mesothelioma. J Thorac Cardiovasc Surg. 2019 02; 157(2):767-768.
Score: 0.538
-
A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma. J Thorac Oncol. 2018 09; 13(9):1400-1409.
Score: 0.520
-
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. 2018 04 05; 3(7).
Score: 0.516
-
Therapeutic R2 resection for pleural mesothelioma. J Thorac Cardiovasc Surg. 2018 06; 155(6):2734-2735.
Score: 0.510
-
Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. Ann Thorac Surg. 2017 Nov; 104(5):1679-1687.
Score: 0.498
-
Invited Commentary. Ann Thorac Surg. 2015 Nov; 100(5):1874.
Score: 0.437
-
CTLA4 blockade in patients with malignant mesothelioma. Lancet Respir Med. 2015 Apr; 3(4):261-3.
Score: 0.419
-
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):30-5.
Score: 0.390
-
Clinical indications and results after chest wall resection for recurrent mesothelioma. J Thorac Cardiovasc Surg. 2013 Dec; 146(6):1373-9; discussion 1379-80.
Score: 0.378
-
Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res. 2012 Mar 15; 18(6):1568-77.
Score: 0.336
-
Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer. 2011 Nov 15; 117(22):5234-44.
Score: 0.319
-
Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy. J Thorac Cardiovasc Surg. 2025 04; 169(4):1082-1095.e4.
Score: 0.203
-
Pleurectomy and decortication are associated with better survival for bicavitary cytoreductive surgery for mesothelioma compared with extrapleural pneumonectomy. J Thorac Cardiovasc Surg. 2023 05; 165(5):1722-1730.
Score: 0.179
-
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma. Br J Cancer. 2022 11; 127(9):1691-1700.
Score: 0.175
-
Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma. Ann Thorac Surg. 2022 11; 114(5):1842-1852.
Score: 0.164
-
Pleurectomy and decortication for metastatic renal cell carcinoma. J Thorac Cardiovasc Surg. 2015 Jul; 150(1):e3-5.
Score: 0.106
-
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
Score: 0.036